Aviles Cesar, Hockenberry Marilyn, Vrochides Dionisios, Iannitti David, Cochran Allyson, Tezber Kendra, Eller Misty, Desamero Janet
Carolinas Medical Center.
Duke University.
Clin J Oncol Nurs. 2017 Aug 1;21(4):466-472. doi: 10.1188/17.CJON.466-472.
BACKGROUND: Pancreatic adenocarcinoma is an aggressive cancer that carries a poor prognosis. Pancreaticoduodenectomy (PD) offers the only potential cure, but the associated morbidity is high. The Enhanced Recovery After Surgery (ERAS) evidence-based guidelines for perioperative care for PD can be used to reduce variations in practice. .
OBJECTIVES: The primary aim was to evaluate the feasibility of the ERAS guidelines for patients undergoing PD. Secondary aims were to assess length of stay (LOS), readmission within 30 days, 30-day mortality, and total surgical complication rates. .
METHODS: Guideline feasibility was evaluated by percentage completion and compliance to each of the perioperative phases of the guideline. Hospital LOS, 30-day readmission, 30-day mortality, and total surgical complication rates were compared before and after ERAS implementation. .
The ERAS guidelines were feasible and safely implemented with no change in LOS, readmission, morbidity, and mortality rates.
胰腺腺癌是一种侵袭性癌症，预后较差。胰十二指肠切除术（PD）是唯一可能治愈的方法，但相关的发病率很高。基于循证医学的胰十二指肠切除术围手术期护理加速康复（ERAS）指南可用于减少实践中的差异。
主要目的是评估ERAS指南在接受胰十二指肠切除术患者中的可行性。次要目的是评估住院时间（LOS）、30天内再入院率、30天死亡率和总手术并发症发生率。
通过完成百分比和对指南围手术期各阶段的依从性来评估指南的可行性。比较了ERAS实施前后的医院住院时间、30天再入院率、30天死亡率和总手术并发症发生率。
ERAS指南是可行的，并且安全实施，住院时间、再入院率、发病率和死亡率均无变化。
